CD8A and neoplasm: This dense, highly crosslinked ECM establishes a physical barrier that limits diffusion and penetration of therapeutics (e.g., chemotherapeutics, nanomedicines) and impedes effector immune-cell infiltration (e.g., CD8+ T cells) into the tumor core, thereby weakening antitumor immunity [149].